GF Fund Management
RXRX icon

GF Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

GF Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$49.7K Buy
12,030
+987
+9% +$3.34K ﹤0.01% 392
2026
Q2 		$40.5K Sell
11,043
-463
-4% -$1.54K ﹤0.01% 412
2026
Q1 		$35.3K Buy
11,506
+1,402
+14% +$5.42K ﹤0.01% 439
2025
Q4 		$41.3K Buy
10,104
+911
+10% +$4.51K ﹤0.01% 421
2025
Q3 		$44.9K Sell
9,193
-582
-6% -$3.06K ﹤0.01% 405
2025
Q2 		$49.5K Hold
9,775
– – ﹤0.01% 415
2025
Q1 		$51.7K Buy
9,775
+1,759
+22% +$12.8K ﹤0.01% 417
2024
Q4 		$54.2K Buy
+8,016
New +$53.9K ﹤0.01% 384

Other funds holding RXRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
MIC Capital Management (UK)
MIC Capital Management (UK) London, United Kingdom $463M AUM 7.9% 1-Year Est. Return

GF Fund Management's RXRX Position: Q3 2026 in Review

GF Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 8.9% in Q3 2026, buying an estimated $3.34K and bringing the position to 12,030 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #392.

GF Fund Management first reported a position in RXRX in Q4 2024 and has held it in 8 quarters since. The position peaked at $54.2K in Q4 2024. 264 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • GF Fund Management held 12,030 shares of Recursion Pharmaceuticals worth $49.7K as of Q3 2026.
  • GF Fund Management bought 987 Recursion Pharmaceuticals shares in Q3 2026, an estimated $3.34K.
  • Recursion Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #392 holding.
  • GF Fund Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Recursion Pharmaceuticals position peaked at $54.2K in Q4 2024.
  • 264 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.